Clinical trial
A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
NCT01743001 is registered in ClinicalTrials.gov with Actelion as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Multi-center, Double-blind, Randomized, Placebo-controlled, Parallel-group, Phase 3 Study to Evaluate the Effects of Macitentan on Exercise Capacity in Subjects With Eisenmenger Syndrome
- Lead sponsor
- Actelion
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- May 21, 2013
- Completion date
- December 1, 2016
- Enrollment
- 226 (actual)
- Sites
- 55
Conditions
As the registry lists them; a condition with its own page is linked.